TransMedics Group (NASDAQ:TMDX) Shares Gap Up – Should You Buy?

TransMedics Group, Inc. (NASDAQ:TMDX) shares gapped up before the market opened on Tuesday . The stock had previously closed at $64.05, but opened at $67.42. TransMedics Group shares last traded at $65.03, with a volume of 673,822 shares.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Piper Sandler decreased their price target on shares of TransMedics Group from $110.00 to $90.00 and set an “overweight” rating for the company in a research note on Wednesday, December 11th. Needham & Company LLC reaffirmed a “hold” rating on shares of TransMedics Group in a report on Wednesday, December 11th. Canaccord Genuity Group cut their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. Robert W. Baird cut their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, TD Cowen dropped their target price on TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, TransMedics Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

TransMedics Group Stock Performance

The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The stock has a 50 day moving average of $72.63 and a 200 day moving average of $119.17. The company has a market capitalization of $2.01 billion, a price-to-earnings ratio of 63.64 and a beta of 2.12.

TransMedics Group (NASDAQ:TMDX) last issued its quarterly earnings results on Monday, October 28th. The company reported $0.12 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.17). TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The business had revenue of $108.76 million during the quarter, compared to analyst estimates of $115.00 million. During the same period last year, the firm posted ($0.12) earnings per share. TransMedics Group’s quarterly revenue was up 63.7% compared to the same quarter last year. As a group, analysts predict that TransMedics Group, Inc. will post 1 EPS for the current year.

Insider Activity at TransMedics Group

In related news, Director Edward M. Basile sold 6,750 shares of the company’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $83.55, for a total value of $563,962.50. Following the transaction, the director now owns 732 shares in the company, valued at approximately $61,158.60. This represents a 90.22 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total value of $93,657.60. Following the sale, the insider now owns 20,843 shares in the company, valued at approximately $1,800,835.20. This represents a 4.94 % decrease in their position. The disclosure for this sale can be found here. 7.00% of the stock is currently owned by insiders.

Institutional Investors Weigh In On TransMedics Group

Several institutional investors have recently made changes to their positions in the stock. Amalgamated Bank lifted its position in shares of TransMedics Group by 6.7% during the second quarter. Amalgamated Bank now owns 1,114 shares of the company’s stock worth $168,000 after acquiring an additional 70 shares in the last quarter. Harbour Capital Advisors LLC raised its position in shares of TransMedics Group by 1.7% in the third quarter. Harbour Capital Advisors LLC now owns 4,841 shares of the company’s stock worth $760,000 after buying an additional 81 shares in the last quarter. Venturi Wealth Management LLC raised its position in shares of TransMedics Group by 33.7% in the third quarter. Venturi Wealth Management LLC now owns 869 shares of the company’s stock worth $136,000 after buying an additional 219 shares in the last quarter. National Bank of Canada FI raised its position in shares of TransMedics Group by 174.7% in the third quarter. National Bank of Canada FI now owns 412 shares of the company’s stock worth $65,000 after buying an additional 262 shares in the last quarter. Finally, Quarry LP increased its stake in TransMedics Group by 557.1% in the third quarter. Quarry LP now owns 368 shares of the company’s stock valued at $58,000 after acquiring an additional 312 shares during the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.